Ireland
--:--IST
Latest
Airmid Éireann Launches: Ireland's Open Pharma Data Project encompass Case Study: NI's Digital Health Record Costs Irish Medtech's GenAI Roadmap: Our Evaluation and POC Log European Accessibility Act: How 27 EU Countries Enforce It Northern Ireland Launches AH&EP to Speed Health Innovation Mergon Acquires Enniscrone Healthcare Moulder Inmo Tech Airmid Éireann Launches: Ireland's Open Pharma Data Project encompass Case Study: NI's Digital Health Record Costs Irish Medtech's GenAI Roadmap: Our Evaluation and POC Log European Accessibility Act: How 27 EU Countries Enforce It Northern Ireland Launches AH&EP to Speed Health Innovation Mergon Acquires Enniscrone Healthcare Moulder Inmo Tech
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kansas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Kansas, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 5309 Florida 4445 Illinois 2491 Georgia 2363 Arizona 2246
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca39 Janssen Research & Development, LLC22 Novartis Pharmaceuticals20 Eli Lilly and Company17 Pfizer16
State
California5309 Florida4445 Illinois2491 Georgia2363 Arizona2246
All 51 states
Target enrolment
to

Trials with a site in Kansas

747 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Boehringer Ingelheim
Phase 3
270
Arizona, California, Colorado, Kansas, Maryland, Massachusetts, Michigan, Minnesota
2026-12-14
Not yet open
Modified SOLTIVE Study
NCT07838077Calculi, Renal, Calculi, Urinary, Benign Prostatic Hyperplasia
Olympus Corporation of the Americas
Observational
250
Kansas
2026-11
Not yet open
Boehringer Ingelheim
Phase 3
600
Arizona, California, Florida, Kansas, New Mexico, North Carolina
2026-10-23
Not yet open
ModernaTX, Inc.
Phase 4
300
Kansas, Kentucky, North Carolina, Tennessee, Texas
2026-10-09
Recruiting
GlaxoSmithKline
Phase 3
3,000
Arizona, California, Florida, Idaho, Indiana, Kansas, New York, South Carolina
2026-10-01
Recruiting
Sanofi
Phase 4
660
California, Florida, Georgia, Illinois, Iowa, Kansas, Louisiana, Maryland
2026-10-01
Not yet open
P+F Products + Features USA Inc.
Not applicable
780
Alabama, Arizona, California, District of Columbia, Florida, Illinois, Indiana, Kansas
2026-10
Recruiting
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
NCT07559175Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
DrugZenpep
Aimmune Nestlé Health Science US R&D, LLC
Phase 2
66
Arizona, Arkansas, California, Florida, Kansas, Maryland, Montana, Ohio
2026-10
Not yet open
Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease
NCT07675408Parkinson's Disease With Freezing of Gait
Fortis Medical Devices Limited
Not applicable
60
Florida, Georgia, Kansas, Oregon, Washington
2026-10
Recruiting
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07729137Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
Emmecell
Phase 2
121
California, Florida, Georgia, Illinois, Indiana, Kansas, Minnesota, Missouri
2026-10
Not yet open
A Study of IBI3042 in Healthy Adult Participants
NCT07842393Healthy Volunteers (HV)
Fortvita Biologics (USA)Inc.
Phase 1
32
Kansas
2026-09-29
Recruiting
Novartis Pharmaceuticals
Phase 2
259
Alabama, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2026-09-29
Recruiting
WiQo S.p.A.
Not applicable
30
Kansas, Oklahoma
2026-09-21
Recruiting
Novartis Pharmaceuticals
Phase 2
180
Alabama, California, Florida, Kansas, Maryland, Texas, Virginia
2026-09-18
Recruiting
Boehringer Ingelheim
Phase 3
466
Alabama, California, Connecticut, Florida, Indiana, Kansas, Michigan, Minnesota
2026-09-17
Recruiting
Novo Nordisk A/S
Phase 3
210
Arizona, California, Connecticut, Florida, Hawaii, Illinois, Iowa, Kansas
2026-09-16
Recruiting
Incyte Corporation
Phase 3
426
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas
2026-09-08
Not yet open
Eli Lilly and Company
Phase 3
170
California, Connecticut, Georgia, Idaho, Kansas, New York, Oklahoma, Pennsylvania
2026-09
Recruiting
Vima Therapeutics
Phase 2
80
Arizona, California, Connecticut, Florida, Georgia, Kansas, Maryland, Michigan
2026-09
Recruiting
Deciphera Pharmaceuticals, LLC
Phase 1
20
Kansas
2026-09
Recruiting
GlaxoSmithKline
Phase 2
274
Kansas, Texas
2026-08-31
Recruiting
Genentech, Inc.
Phase 1
139
Kansas
2026-08-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
960
California, Colorado, Connecticut, Florida, Kansas, Maryland, Mississippi, New Jersey
2026-08-27
Recruiting
Pfizer
Phase 3
400
Arizona, California, Florida, Indiana, Kansas, Massachusetts, Michigan, Missouri
2026-08-26
Recruiting
AstraZeneca
Phase 3
1,500
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas
2026-08-20
Recruiting
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
DrugsMRT-2359·Apalutamide
Monte Rosa Therapeutics, Inc
Phase 2
25
California, Colorado, Kansas, Maryland, Michigan, Nebraska, New Jersey, North Carolina
2026-08-18
Recruiting
Bausch Health Americas, Inc.
Phase 2
180
Alabama, Arkansas, California, Florida, Georgia, Kansas, Louisiana, Maryland
2026-08-18
Recruiting
Novo Nordisk A/S
Phase 1
142
Kansas, Texas
2026-08-12
Not yet open
Distalmotion SA
Observational
112
Kansas, Texas
2026-08-07
Recruiting
Sanofi
Observational
350
Indiana, Kansas, North Carolina, Ohio, Texas
2026-08-06
Recruiting
Viatris Inc.
Phase 4
60
Kansas
2026-08-03
Recruiting
Sanofi
Phase 1/2
640
Arizona, California, Florida, Georgia, Illinois, Kansas, New York, South Carolina
2026-08-03
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Alabama, California, Florida, Georgia, Idaho, Illinois, Kansas, Missouri
2026-07-31
Recruiting
Amgen
Phase 3
950
Arizona, California, Florida, Illinois, Iowa, Kansas, Louisiana, Maryland
2026-07-29
Recruiting
Regeneron Pharmaceuticals
Phase 2
360
Alabama, California, Connecticut, Florida, Illinois, Kansas, Kentucky, Nebraska
2026-07-28
Recruiting
Freya Biosciences ApS
Phase 2
30
Kansas, Massachusetts, North Carolina, Texas
2026-07-22
Recruiting
Insmed Incorporated
Phase 3
344
California, Kansas, Nebraska, New York, Pennsylvania, South Carolina
2026-07-21
Active, closed
AstraZeneca
Phase 1/2
164
California, Illinois, Kansas, Missouri, Nebraska
2026-07-08
Recruiting
AstraZeneca
Phase 3
800
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Kentucky
2026-07-06
Recruiting
Prilenia
Phase 3
400
Alabama, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2026-07-01
Recruiting
Expedition Therapeutics, Inc
Phase 2
600
Arizona, California, Colorado, Florida, Georgia, Indiana, Kansas, Minnesota
2026-06-30
Active, closed
Moonlight Therapeutics, Inc.
Phase 1
40
Arkansas, Georgia, Kansas, Michigan, North Carolina
2026-06-29
Recruiting
Biohaven Therapeutics Ltd.
Phase 3
300
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana
2026-06-26
Recruiting
Novo Nordisk A/S
Phase 2
300
Alabama, California, Florida, Indiana, Kansas, Maryland, North Carolina, North Dakota
2026-06-22
Active, closed
TScan Therapeutics, Inc.
Phase 3
310
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2026-06-18
Recruiting
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07581184Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC
Aktis Oncology, Inc.
Phase 1
138
California, Florida, Kansas, Massachusetts, Michigan, Nebraska
2026-06-17
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
NCT07637734Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
300
California, Florida, Illinois, Kansas, Louisiana, Massachusetts, Minnesota, Nebraska
2026-06-15
Recruiting
argenx
Phase 3
230
California, Florida, Kansas, Michigan, Missouri, New York, Texas
2026-06-10
Recruiting
Novartis Pharmaceuticals
Phase 1
152
Kansas, Texas, Utah
2026-06-09
Active, closed
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
NCT07678775Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
DrugRibitol
ML Bio Solutions, Inc.
Phase 3
107
Arkansas, California, Colorado, Florida, Iowa, Kansas, Maryland, Minnesota
2026-06-05
Recruiting
GlaxoSmithKline
Phase 1/2
1,456
Georgia, Kansas, Washington
2026-06-05
Recruiting
AbbVie
Phase 2/3
576
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maine
2026-06-01
Recruiting
Celldex Therapeutics
Phase 1
12
California, Kansas, Massachusetts, Pennsylvania
2026-06-01
Recruiting
Novartis Pharmaceuticals
Phase 2
120
Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-29
Recruiting
Vericel Corporation
Phase 3
309
California, District of Columbia, Kansas, North Carolina, Texas, Virginia
2026-05-28
Recruiting
Novartis Pharmaceuticals
Phase 1
194
Connecticut, Kansas, Texas
2026-05-28
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
California, Colorado, Connecticut, Illinois, Iowa, Kansas, Massachusetts, Michigan
2026-05-28
Recruiting
Claris Biotherapeutics, Inc.
Observational
500
Indiana, Kansas, Kentucky, Minnesota, Oregon, Tennessee, Texas
2026-05-22
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Massachusetts
2026-05-20
By invitation
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
NCT07393594Kidney Diseases, Kidney Injury, BK Virus Infection, CMV
Transplant Genomics, Inc.
Observational
1,000
Arizona, California, Kansas, Michigan, New Hampshire, New Jersey, New York, North Carolina
2026-05-19
Recruiting
Eli Lilly and Company
Phase 2
400
Arizona, California, Connecticut, Florida, Idaho, Illinois, Kansas, Kentucky
2026-05-15
Active, closed
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
DrugsPF-08653945·Berobenatide
Pfizer
Phase 2
940
Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 2
323
California, Florida, Georgia, Illinois, Kansas, Maryland, Michigan, Missouri
2026-05-07
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
Arizona, California, Delaware, Florida, Kansas, Massachusetts, Minnesota, Nebraska
2026-05-06
Recruiting
AstraZeneca
Observational
2,150
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Maryland
2026-05-06
Recruiting
AstraZeneca
Phase 3
420
California, Colorado, Connecticut, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2026-05-05
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
By invitation
Axsome Therapeutics, Inc.
Phase 3
300
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2026-04-29
Recruiting
Phase 2 Study to Assess the Safety and Efficacy of ANG003
NCT07450547Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Anagram Therapeutics, Inc.
Phase 2
113
California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky, Maine
2026-04-24
Active, closed
Resilient Pharmaceuticals
Phase 1
32
Kansas
2026-04-23
Recruiting
Inhibikase Therapeutics
Phase 3
486
Arizona, California, Colorado, Kansas, Kentucky, Massachusetts, Missouri, New York
2026-04-23
Recruiting
Alkermes, Inc.
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-22
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Alabama, California, Colorado, Connecticut, Florida, Georgia, Iowa, Kansas
2026-04-21
Recruiting
Mediar Therapeutics
Phase 2
85
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Minnesota
2026-04-16
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT07496567Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Kansas
2026-04-15
Recruiting
Ambros Therapeutics, Inc.
Phase 3
270
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2026-04-14
Active, closed
Novo Nordisk A/S
Phase 1
41
Kansas
2026-04-07
Recruiting
Alkermes, Inc.
Phase 3
150
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-06
Not yet open
Electronic Waveform Lab
Not applicable
80
Kansas, Missouri
2026-04-01
Recruiting
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
NCT07439653Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TORL Biotherapeutics, LLC
Phase 1/2
155
California, Florida, Iowa, Kansas, Tennessee, Texas
2026-03-31
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
California, Colorado, Florida, Georgia, Kansas, Louisiana, Missouri
2026-03-24
Recruiting
Zenas BioPharma (USA), LLC
Phase 3
705
Arizona, California, Florida, Kansas, Missouri, New Jersey, North Carolina, Ohio
2026-03-23
Recruiting
Amgen
Phase 3
406
Connecticut, Florida, Kansas, Maryland, Pennsylvania, Texas
2026-03-23
Recruiting
Zenas BioPharma (USA), LLC
Phase 3
990
Arizona, California, Florida, Indiana, Kansas, Massachusetts, Michigan, Missouri
2026-03-23
Recruiting
Sanofi
Phase 2/3
526
California, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan, New York
2026-03-13
Recruiting
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT07477639Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
DrugBendamustine
Tr1X, Inc.
Phase 1/2
39
California, Kansas, Minnesota, Missouri, New York, North Carolina, Ohio, Washington
2026-03-01
Recruiting
Boehringer Ingelheim
Phase 2
30
Arizona, California, Colorado, Florida, Georgia, Iowa, Kansas, Maryland
2026-02-27
Recruiting
Appello Pharmaceuticals, Inc.
Phase 2
150
Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky
2026-02-25
Recruiting
Novo Nordisk A/S
Phase 1
132
Kansas
2026-02-24
Recruiting
Pfizer
Phase 2/3
1,156
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2026-02-11
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
80
California, Colorado, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2026-02-10
Recruiting
AstraZeneca
Phase 2
124
Arizona, California, Kansas, Maryland, Massachusetts, Michigan, New York, North Carolina
2026-02-10
Active, closed
Vaxcyte, Inc.
Phase 3
752
Arizona, Connecticut, Florida, Georgia, Indiana, Kansas, Louisiana, Maryland
2026-02-09
Recruiting
Vima Therapeutics
Phase 2
100
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2026-02-05
Recruiting
AbbVie
Phase 2
200
California, Florida, Illinois, Kansas, Minnesota, North Carolina, Ohio, Pennsylvania
2026-02-04
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Alabama, California, Colorado, Connecticut, Florida, Indiana, Kansas, Michigan
2026-02-02
Recruiting
Novo Nordisk A/S
Phase 2
333
California, Kansas
2026-02-02
Recruiting
Incyte Corporation
Phase 2
40
Alabama, Arizona, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2026-02-02
Recruiting
Prilenia
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland
2026-02-01
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kansas, Kentucky
2026-01-28
Recruiting
Corcept Therapeutics
Phase 2
80
Arizona, California, Florida, Georgia, Indiana, Kansas, Michigan, Minnesota
2026-01-27
Recruiting
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07287917Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
DrugsDifluoromethylornithine·DFMO·Capivasertib·Fulvestrant
Aminex Therapeutics, Inc.
Phase 1/2
92
Arizona, California, Colorado, Kansas, Michigan, Minnesota, New York, Ohio
2026-01-26
Recruiting
Generate Biomedicines
Phase 3
786
California, Florida, Kansas, Massachusetts, Michigan, New York, Ohio, Oklahoma
2026-01-20
Recruiting
Sun Pharmaceutical Industries Limited
Phase 2
285
Arkansas, Florida, Kansas, Oklahoma
2026-01-20
Active, closed
Medtronic Cardiac Ablation Solutions
Not applicable
300
Arkansas, California, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2026-01-15
Recruiting
Axsome Therapeutics, Inc.
Phase 3
620
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas
2026-01-14
Recruiting
Takeda
Phase 3
183
Alabama, California, Kansas, Maryland, Michigan, Missouri, New York
2026-01-14
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Alabama, Iowa, Kansas, North Carolina, South Carolina, Utah
2026-01-13
Recruiting
Merck Sharp & Dohme LLC
Phase 1
210
California, Florida, Kansas, Kentucky, Maryland, Missouri, New York, South Carolina
2026-01-13
Active, closed
Vaxcyte, Inc.
Phase 3
1,390
Arizona, Colorado, Florida, Indiana, Kansas, Kentucky, Michigan, Nebraska
2026-01-12
Recruiting
Alnylam Pharmaceuticals
Observational
2,000
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, New Jersey
2026-01-09
Active, closed
Arsenal Biosciences, Inc.
Phase 1/2
190
California, Colorado, Iowa, Kansas, Minnesota, New York, Washington
2026-01-09
Recruiting
Enveda Therapeutics
Phase 2
50
Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky
2026-01-09
Active, closed
Invivyd, Inc.
Phase 3
1,770
California, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2026-01-08
Recruiting
Novo Nordisk A/S
Phase 3
460
California, Florida, Georgia, Idaho, Indiana, Kansas, Louisiana, Maryland
2026-01-08
Recruiting
Insmed Incorporated
Phase 3
344
Arizona, California, Florida, Kansas, New York, North Carolina, Ohio, Oregon
2026-01-07
Recruiting
Biogen
Phase 2
81
California, Colorado, Kansas, Michigan, Minnesota, Missouri, Nebraska, New Jersey
2026-01-05
Recruiting
Maxx Orthopedics Inc
Not applicable
200
Kansas, Texas
2026-01-01
Active, closed
Kailera
Phase 3
1,270
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas
2025-12-30
Recruiting
Sanofi
Phase 2
144
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky
2025-12-29
Recruiting
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
NCT07333183Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
20
California, Florida, Illinois, Kansas, Massachusetts, Michigan, New Mexico, North Carolina
2025-12-23
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-12-19
Recruiting
Abuse Liability for Five Modern Oral Nicotine Products
NCT07132814Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
RAI Services Company
Not applicable
40
Kansas
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-12-15
Recruiting
GlaxoSmithKline
Phase 3
1,250
California, Florida, Kansas, Louisiana, Missouri, New Jersey, New York, North Carolina
2025-12-12
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 1
136
Kansas
2025-12-09
Active, closed
AstraZeneca
Phase 2
222
Arizona, Florida, Georgia, Illinois, Kansas, North Carolina, Ohio, Pennsylvania
2025-12-05
Active, closed
Vaxcyte, Inc.
Phase 3
4,049
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2025-12-01
Recruiting
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484Type 2 Diabetes, Cortisol Excess
DrugClofutriben
Sparrow Pharmaceuticals
Phase 2
1,500
Arizona, California, Florida, Georgia, Idaho, Illinois, Iowa, Kansas
2025-11-29
Recruiting
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
NCT07209397Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant)
InMode MD Ltd.
Not applicable
202
California, District of Columbia, Idaho, Illinois, Kansas, Massachusetts, Nebraska, Nevada
2025-11-25
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,000
California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-11-24
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugVX-407
Vertex Pharmaceuticals Incorporated
Phase 2
26
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-11-19
Recruiting
ACADIA Pharmaceuticals Inc.
Phase 3
126
California, Florida, Hawaii, Kansas, New York, Ohio, Oklahoma, Texas
2025-11-14
Active, closed
Pfizer
Phase 2
128
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-11-13
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
NCT07085104Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
DrugsFludarabine·Cyclophosphamide
Allogene Therapeutics
Phase 1
66
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky
2025-11-13
Active, closed
Boehringer Ingelheim
Phase 2
81
Alabama, Florida, Iowa, Kansas, Minnesota, Missouri, New York, North Carolina
2025-11-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
996
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2025-11-11
By invitation
Impact of Anatomy-Based Cochlear Implant Programming on Early Performance
NCT06734039Hearing Loss, Unilateral, Cochlear Implants, Hearing Loss, Sensorineural, Single-Sided Deafness (SSD)
Med-El Corporation
Not applicable
50
Iowa, Kansas, North Carolina, Oregon, Pennsylvania
2025-11-10
Recruiting
AstraZeneca
Phase 1
40
Alabama, California, Florida, Kansas, Maryland, Minnesota, Texas
2025-11-10
Recruiting
AstraZeneca
Phase 2
435
California, Colorado, District of Columbia, Florida, Georgia, Kansas, Michigan, Minnesota
2025-11-06
Recruiting
Pfizer
Phase 1
294
Alabama, Florida, Georgia, Illinois, Iowa, Kansas, New Jersey, New York
2025-11-06
Recruiting
CCM OPEN HF Registry
NCT07112924Heart Failure
Impulse Dynamics
Observational
5,500
Arizona, Florida, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New Hampshire
2025-11-01
Recruiting
Maxx Orthopedics Inc
Observational
300
Kansas, Texas
2025-11-01
Active, closed
Abbott Medical Devices
Not applicable
11
Kansas, Minnesota, New York
2025-10-30
Active, closed
Bavarian Nordic
Phase 2
970
Iowa, Kansas, New York, North Carolina, South Carolina, Tennessee, Texas, Virginia
2025-10-27
Recruiting
GlaxoSmithKline
Phase 3
1,200
Arizona, Arkansas, California, Colorado, Florida, Georgia, Kansas, Louisiana
2025-10-24
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Kansas
2025-10-23
Recruiting
Biosense Webster, Inc.
Not applicable
276
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Michigan
2025-10-21
Recruiting
Virtue® SAB in the Treatment of Coronary ISR Trial
NCT07045194Coronary Artery Disease
Orchestra BioMed, Inc
Not applicable
740
Florida, Indiana, Kansas, Maryland, Michigan, New York, North Carolina, Ohio
2025-10-20
Recruiting
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
NCT07143669Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
Blueprint Medicines Corporation
Observational
750
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana
2025-10-17
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Colorado, Florida, Georgia, Kansas, Massachusetts, North Carolina, Ohio, Washington
2025-10-15
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
56
California, Kansas, Texas
2025-10-13
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-03
Recruiting
Janssen Research & Development, LLC
Phase 3
882
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-01
Recruiting
AllRock Bio, Inc.
Phase 2
40
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Michigan, Ohio
2025-10-01
Recruiting
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
NCT07215923Thromboangiitis Obliterans (Buerger's Disease)
Antidote Therapeutics, Inc
Phase 1
15
Kansas
2025-10
Recruiting
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
200
California, Florida, Illinois, Kansas, New York, North Carolina, Pennsylvania, Washington
2025-09-30
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
Arizona, California, Colorado, Connecticut, Florida, Iowa, Kansas, Kentucky
2025-09-26
Recruiting
Sanofi
Phase 4
218
Alabama, Florida, Georgia, Kansas, Maryland, Massachusetts, North Carolina, Pennsylvania
2025-09-22
Recruiting
Study of Student Flourishing
NCT07259746Healthy
Flourish Science, Inc.
Not applicable
2,500
California, Colorado, Hawaii, Kansas, Rhode Island, Washington, Wisconsin
2025-09-22
Recruiting
DESTINY-PANTUMOUR04
NCT07124000Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Observational
100
Alabama, Arizona, California, Colorado, Florida, Illinois, Kansas, New Mexico
2025-09-18
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
DrugsAZD0754·AZD5851
AstraZeneca
Observational
64
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, Missouri
2025-09-17
Recruiting
Sanofi
Phase 3
942
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana
2025-09-16
Recruiting
Teikoku Pharma USA, Inc.
Phase 2
150
California, Florida, Kansas, Massachusetts, New Jersey
2025-09-16
Recruiting
Vanda Pharmaceuticals
Phase 2
240
Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky, Missouri
2025-09-15
Active, closed
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Kansas, Massachusetts
2025-09-15
Recruiting
CSL Behring
Phase 3
200
California, Georgia, Illinois, Kansas, Maryland, New Jersey, New York, Ohio
2025-09-15
Recruiting
Annexon, Inc.
Phase 3
30
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-09-12
Active, closed
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
NCT07207408Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis
Dynavax Technologies Corporation
Phase 2
148
Florida, Kansas, Nevada, Ohio
2025-09-11
Recruiting
Lumbar & Sacroiliac Fusion Study Involving Previously Implanted Devices
NCT07204288Fusion of Spine, Sacroiliac; Fusion
Spinal Simplicity LLC
Not applicable
500
Kansas, Minnesota
2025-09-11
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1
32
Kansas
2025-09-10
Recruiting
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
NCT06784466Atrial Fibrillation (AF), Persistant Atrial Fibrillation, Paroxysmal AF
Arga Medtech SA
Not applicable
360
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas
2025-09-10
Active, closed
AstraZeneca
Phase 1/2
405
California, Florida, Georgia, Illinois, Kansas, Missouri, Nebraska, Nevada
2025-09-04
Recruiting
Neuspera Medical, Inc.
Not applicable
116
California, Florida, Indiana, Kansas, Kentucky, Louisiana, Michigan, Minnesota
2025-09-03
Recruiting
Opus Genetics, Inc
Phase 3
580
Arizona, California, Florida, Illinois, Kansas, Massachusetts, North Carolina, Pennsylvania
2025-09-02
Recruiting
BeOne Medicines
Phase 3
351
Arizona, California, Colorado, Florida, Illinois, Kansas, Maine, Missouri
2025-08-27
Recruiting
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07020117Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
Aktis Oncology, Inc.
Phase 1
150
California, Florida, Iowa, Kansas, Maryland, Michigan, New York, Pennsylvania
2025-08-22
Active, closed
Merz Therapeutics GmbH
Phase 3
808
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Kansas
2025-08-21
Active, closed
Merz Therapeutics GmbH
Phase 3
997
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Kansas
2025-08-21
Recruiting
Abbott Cephea Mitral Valve Disease Registry
NCT07069673Mitral Regurgitation, Mitral Stenosis, Mitral Valve Disease, Mitral Valve (MV) Regurgitation
Abbott Medical Devices
Observational
1,000
Alabama, Arizona, California, Georgia, Illinois, Indiana, Kansas, Minnesota
2025-08-13
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, Nevada
2025-08-07
Recruiting
ACADIA Pharmaceuticals Inc.
Phase 2
180
California, Colorado, District of Columbia, Florida, Hawaii, Illinois, Kansas, New York
2025-08-06
Recruiting
Delcath Systems Inc.
Phase 2
90
California, Florida, Kansas, Louisiana, Utah
2025-08-05
Recruiting
Inspire Medical Systems, Inc.
Observational
70
Colorado, Florida, Illinois, Kansas, New York
2025-07-31
Recruiting
Shionogi
Phase 1
98
Kansas, Utah
2025-07-29
Recruiting
Reprieve Cardiovascular, Inc
Not applicable
400
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Minnesota
2025-07-28
Recruiting
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
Arizona, California, Colorado, District of Columbia, Georgia, Illinois, Indiana, Kansas
2025-07-25
Active, closed
Pharmacokinetics of Zelquistinel in Fasted or Fed State
NCT07099989Healthy Volunteers in Fed and Fasted State
DrugZelquistinel
Syndeio Biosciences, Inc
Phase 1
32
Kansas
2025-07-24
Recruiting
Eli Lilly and Company
Phase 1
104
California, Kansas, Texas, Utah
2025-07-24
Recruiting
Celcuity Inc
Phase 3
1,180
Arkansas, California, Colorado, Florida, Kansas, Kentucky, Maryland, Massachusetts
2025-07-24
Recruiting
Pfizer
Phase 3
714
California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maine, Massachusetts
2025-07-23
Active, closed
Pfizer
Phase 1
380
California, Florida, Kansas, Missouri, Nebraska, New York, North Carolina, Ohio
2025-07-22
Recruiting
Teleflex
Not applicable
150
California, Kansas, Massachusetts, Michigan, Missouri, New York, Texas, West Virginia
2025-07-18
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
California, District of Columbia, Kansas, Maryland, Missouri, New York, North Carolina, Ohio
2025-07-18
Recruiting
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
NCT06950385Familial Adenomatous Polyposis (FAP)
DrugERapa
Rapamycin Holdings Inc.
Phase 3
168
California, Connecticut, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-07-18
Recruiting
AstraZeneca
Phase 2
100
Delaware, District of Columbia, Kansas, Michigan, New York, Pennsylvania
2025-07-17
Recruiting
Apreo Health, Inc.
Not applicable
250
Alabama, Arizona, California, Florida, Illinois, Kansas, Massachusetts, Michigan
2025-07-15
Recruiting
Shield Post-Approval Study Protocol
NCT06880055Colo-rectal Cancer
Guardant Health, Inc.
Observational
3,375
Arizona, California, Connecticut, Florida, Illinois, Kansas, Louisiana, Michigan
2025-07-14
Recruiting
Harbinger Health
Observational
2,450
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Louisiana
2025-07-11
Recruiting
ELEVATE-HFpEF Clinical Study
NCT06678841Heart Failure With Preserved Ejection Fraction (HFpEF)
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
700
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2025-07-09
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Arizona, California, Connecticut, Kansas, Michigan, New York, North Carolina, Ohio
2025-07-02
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
90
Alabama, Arkansas, California, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-06-27
Active, closed
Monte Rosa Therapeutics, Inc
Phase 1
100
Florida, Kansas, Missouri, Texas
2025-06-27
By invitation
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
Avidity Biosciences, Inc.
Phase 3
199
California, Colorado, Florida, Indiana, Kansas, Maryland, Massachusetts, Minnesota
2025-06-26
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Arizona, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-06-23
Active, closed
Calluna Pharma AS
Phase 2
150
California, Colorado, Florida, Kansas, North Carolina, Ohio, Pennsylvania, Utah
2025-06-20
Recruiting
Stryker Neurovascular
Not applicable
183
Arizona, California, Florida, Kansas, Massachusetts, New York, Ohio, Oregon
2025-06-20
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Missouri
2025-06-19
Recruiting
BlueRock Therapeutics
Phase 3
102
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas
2025-06-17
Recruiting
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
NCT06552416Acute Myeloid Leukemia, in Relapse, MDS
Marker Therapeutics, Inc.
Phase 1
40
California, Florida, Kansas
2025-06-16
Recruiting
Cerus Endovascular, Inc.
Not applicable
250
Illinois, Kansas, New York, North Carolina, Pennsylvania, South Carolina, Washington
2025-06-10
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
DrugDel-brax
Avidity Biosciences, Inc.
Phase 3
200
California, Colorado, Florida, Iowa, Kansas, Maryland, Massachusetts, New York
2025-06-10
Recruiting
Celgene
Phase 2
200
Alabama, Arizona, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri
2025-06-05
Recruiting
Boehringer Ingelheim
Phase 2
300
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-06-05
Recruiting
Sanofi
Phase 2
99
Arizona, California, Florida, Georgia, Iowa, Kansas, Massachusetts, Michigan
2025-06-03
Recruiting
Syncromune, Inc.
Phase 2
91
Arizona, Arkansas, California, Florida, Illinois, Kansas, Louisiana, Michigan
2025-05-29
Active, closed
Eli Lilly and Company
Phase 3
586
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-05-29
Recruiting
Biohaven Therapeutics Ltd.
Phase 2/3
550
Alabama, California, Colorado, Connecticut, Florida, Illinois, Kansas, Massachusetts
2025-05-28
Recruiting
Regeneron Pharmaceuticals
Phase 2
297
Alabama, California, Florida, Illinois, Kansas, Kentucky, Massachusetts, Michigan
2025-05-28
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
California, Colorado, Florida, Illinois, Kansas, Kentucky, Louisiana, Maryland
2025-05-27
Recruiting
Boehringer Ingelheim
Phase 3
4,200
California, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Louisiana
2025-05-20
Recruiting
Pfizer
Phase 2
252
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kansas, Michigan
2025-05-20
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2025-05-19
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maryland, Michigan
2025-05-15
Recruiting
GC Biopharma Corp
Phase 1/2
18
California, Kansas, Minnesota, Ohio, Pennsylvania, Virginia
2025-05-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
130
Colorado, Kansas, New Mexico
2025-05-12
Recruiting
Hoffmann-La Roche
Phase 3
425
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-05-12
Active, closed
OrthoTrophix, Inc
Phase 2
270
Arizona, California, Florida, Georgia, Kansas, Kentucky, Louisiana, Minnesota
2025-05-09
Active, closed
Cartesian Therapeutics
Phase 3
128
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2025-05-06
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-05-06
Active, closed
Mediar Therapeutics
Phase 2
168
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-05-05
Recruiting
Avvio Medical
Not applicable
101
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Minnesota
2025-05-01
Recruiting
Gilead Sciences
Phase 1/2
100
California, Georgia, Kansas, Missouri, Tennessee, Texas, Virginia
2025-04-30
Active, closed
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468Post Bariatric Hypoglycemia
Amylyx Pharmaceuticals Inc.
Phase 3
75
California, Colorado, Florida, Georgia, Kansas, Massachusetts, New York, North Carolina
2025-04-29
Recruiting
AbbVie
Phase 2
315
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas
2025-04-29
Recruiting
Takeda
Observational
30
California, Connecticut, Florida, Hawaii, Illinois, Kansas, North Carolina
2025-04-29
Active, closed
Hoffmann-La Roche
Phase 1
50
California, Florida, Illinois, Kansas, New York, Pennsylvania, Texas
2025-04-28
Recruiting
Endevica Bio
Phase 2
120
Arizona, California, Florida, Georgia, Illinois, Kansas, Michigan, Nebraska
2025-04-28
Recruiting
Innoviva Specialty Therapeutics
Observational
100
California, Florida, Kansas, Kentucky, Louisiana, New York, Ohio, Pennsylvania
2025-04-28
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
Perspective Therapeutics
Phase 1/2
112
California, Florida, Kansas, Kentucky, Minnesota, Missouri, Nebraska, New York
2025-04-28
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
260
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Kansas
2025-04-24
Recruiting
Arrowhead Pharmaceuticals
Phase 3
288
California, Connecticut, Illinois, Indiana, Kansas, Michigan, Missouri, Nebraska
2025-04-24
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
Tyra Biosciences, Inc
Phase 1
125
California, Kansas, Maryland, Massachusetts, Michigan, New York, Tennessee
2025-04-24
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Maryland
2025-04-17
Recruiting
Pfizer
Phase 3
550
Alabama, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas
2025-04-16
By invitation
Regeneron Pharmaceuticals
Phase 2
48
California, Colorado, Kansas, Michigan, New Jersey, Tennessee, Texas, Virginia
2025-04-14
Recruiting
AstraZeneca
Phase 3
830
California, Delaware, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky
2025-04-10
Recruiting
W.L.Gore & Associates
Not applicable
180
Arizona, California, Florida, Illinois, Kansas, Maryland, Michigan, Mississippi
2025-04-09
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
California, Florida, Georgia, Illinois, Indiana, Kansas, Maryland, Michigan
2025-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Alabama, Alaska, California, Connecticut, Florida, Georgia, Indiana, Kansas
2025-04-09
Recruiting
Incyte Corporation
Phase 3
572
California, Florida, Georgia, Indiana, Kansas, Massachusetts, Michigan, Missouri
2025-04-02
Active, closed
TECTONIC CAD IVL IDE Study
NCT06885177Coronary Artery Calcification, Coronary Artery Disease, Stenotic Coronary Lesion
Abbott Medical Devices
Not applicable
335
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2025-04-01
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Alabama, Arizona, Kansas, Pennsylvania
2025-04-01
Recruiting
AstraZeneca
Phase 2
540
California, Delaware, Florida, Idaho, Indiana, Iowa, Kansas, Kentucky
2025-03-26
Active, closed
Acoustic Wave Cell Therapy, Inc.
Not applicable
130
Arizona, Florida, Idaho, Kansas, Montana, Nevada, Ohio, Texas
2025-03-25
Active, closed
TrueBinding, Inc.
Phase 2
62
California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan, New York
2025-03-20
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2025-03-18
Active, closed
Safety and Efficacy of VDPHL01 in Males With AGA
NCT06972264Androgenetic Alopecia, AGA, Male Pattern Baldness
DrugVDPHL01
Veradermics, Inc.
Phase 3
480
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-03-11
Active, closed
Bavarian Nordic
Phase 2
411
California, Georgia, Kansas, Kentucky, Louisiana, Missouri, Nebraska, Texas
2025-03-10
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
DrugALXN2030
Alexion Pharmaceuticals, Inc.
Phase 2
47
Alabama, Arizona, California, Florida, Georgia, Kansas, Michigan, New Jersey
2025-03-07
Recruiting
AbbVie
Phase 1/2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas, Massachusetts
2025-03-06
Recruiting
Daiichi Sankyo
Phase 3
726
Connecticut, Illinois, Kansas, Maryland, Massachusetts, Michigan, Minnesota, New York
2025-02-27
By invitation
Axsome Therapeutics, Inc.
Phase 3
236
California, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri, New Jersey
2025-02-20
Active, closed
Essilor International
Not applicable
91
Illinois, Kansas, Massachusetts, New York
2025-02-18
Recruiting
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT06847321Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Lighthouse Pharmaceuticals, Inc.
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Kansas, Louisiana, Maryland
2025-02-17
Recruiting
VIVEX Biologics, Inc.
Not applicable
325
California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky, Louisiana
2025-02-17
Recruiting
Impax Laboratories, LLC
Phase 4
220
Arizona, Arkansas, California, Florida, Illinois, Kansas, Michigan, Nevada
2025-02-12
Recruiting
AbbVie
Phase 3
130
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana
2025-02-11
Recruiting
Maze Therapeutics
Phase 2
74
Alabama, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas, Kentucky
2025-02-05
Recruiting
Syndeio Biosciences, Inc
Phase 2
164
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2025-02-03
Recruiting
BOOM-IBD2 Pivotal Clinical Trial
NCT06571669Ulcerative Colitis, Inflammatory Bowel Diseases
Boomerang Medical
Not applicable
137
California, Kansas, Minnesota, Mississippi, Missouri, Nevada, New York, North Carolina
2025-01-31
By invitation
Verismo Therapeutics
Observational
60
Colorado, Georgia, Kansas, New Jersey, Pennsylvania, Texas, Wisconsin
2025-01-27
Recruiting
BeOne Medicines
Phase 1/2
258
Florida, Indiana, Kansas, Massachusetts, Missouri, Washington
2025-01-23
Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)
Neuron23 Inc.
Phase 2
150
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-01-17
Active, closed
Mylan Pharmaceuticals Inc
Phase 3
1,630
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky
2025-01-13
Recruiting
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
NCT06011551Degenerative Disc Disease (DDD)
ReGelTec, Inc.
Not applicable
225
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kansas, Louisiana
2025-01-13
Recruiting
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
NCT06733675Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI)
DrugsAmoxicillin-clavulanate·Esomeprazole
Basilea Pharmaceutica
Phase 1
96
Kansas
2025-01-07
Recruiting
Atea Pharmaceuticals, Inc.
Phase 1
32
Florida, Kansas, New Jersey
2025-01-07
Active, closed
Coherus Oncology, Inc.
Phase 2
72
Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky, Mississippi
2024-12-20
Active, closed
Vertex Pharmaceuticals Incorporated
Observational
401
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2024-12-19
Active, closed
Immunis, Inc.
Phase 2
55
California, Kansas
2024-12-19
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 3
1,714
Arizona, Arkansas, California, District of Columbia, Florida, Idaho, Kansas, Maryland
2024-12-18
Recruiting
Cabaletta Bio
Phase 1/2
24
California, Colorado, Florida, Illinois, Kansas, Massachusetts, Minnesota, New York
2024-12-17
Recruiting
Boehringer Ingelheim
Phase 2
80
Arizona, Colorado, Florida, Illinois, Kansas, New York, North Carolina, Texas
2024-12-11
Active, closed
Vicore Pharma AB
Phase 2
378
Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2024-12-09
Active, closed
Janssen Research & Development, LLC
Phase 3
655
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Michigan
2024-12-04
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Arizona, California, District of Columbia, Illinois, Indiana, Kansas, Maryland, Massachusetts
2024-12-03
Recruiting
OSE Immunotherapeutics
Phase 3
363
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas, Louisiana
2024-12-03
Active, closed
Biogen
Phase 3
132
California, Colorado, Illinois, Kansas, Louisiana, Minnesota, Missouri, Nebraska
2024-12-03
Recruiting
CoMind Early Feasibility Study
NCT06368648Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage
CoMind Technologies Limited
Observational
581
Arizona, California, Delaware, District of Columbia, Florida, Iowa, Kansas, Missouri
2024-11-27
Recruiting
BeOne Medicines
Phase 1/2
80
Arizona, California, Florida, Kansas, Minnesota, Missouri, New York, Pennsylvania
2024-11-27
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Arizona, California, Florida, Illinois, Iowa, Kansas, Minnesota, Missouri
2024-11-27
Recruiting
GlaxoSmithKline
Phase 3
750
Arizona, California, Florida, Illinois, Kansas, Louisiana, Minnesota, Nebraska
2024-11-26
Active, closed
CereVasc Inc
Not applicable
230
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Massachusetts
2024-11-26
Recruiting
RTI Surgical
Not applicable
467
Arkansas, California, Colorado, Kansas, Missouri, New York, Ohio, Oklahoma
2024-11-22
Recruiting
Deciphera Pharmaceuticals, LLC
Phase 2
48
California, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts, Michigan
2024-11-21
Active, closed
Brixton Biosciences, Inc.
Not applicable
263
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2024-11-19
Recruiting
GlaxoSmithKline
Phase 1/2
448
Kansas, New Jersey, New York, Texas, Washington
2024-11-19
Recruiting
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
NCT06603246Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease
Genentech, Inc.
Phase 1
128
Alabama, California, Kansas, North Carolina, Pennsylvania, Texas
2024-11-18
Recruiting
GigaGen, Inc.
Phase 1
48
Arizona, California, Georgia, Iowa, Kansas, Maryland, Texas, Virginia
2024-11-13
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 1/2
1,530
Arizona, California, Colorado, District of Columbia, Florida, Idaho, Kansas, Maryland
2024-11-11
Active, closed
Sanofi
Phase 2
556
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-11-07
Active, closed
Abbott Medical - VERITAS Study
NCT06707688Atrial Fibrillation (AF), Stoke
Abbott Medical Devices
Not applicable
458
Arizona, Arkansas, Florida, Georgia, Kansas, Michigan, Minnesota, Nebraska
2024-11-07
Recruiting
argenx
Observational
680
California, Florida, Illinois, Iowa, Kansas, Kentucky, Massachusetts, Michigan
2024-11-04
Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NCT06733935Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
DrugsNKX019·Fludarabine·Cyclophosphamide
Nkarta, Inc.
Phase 1/2
240
California, Florida, Illinois, Kansas, Michigan, Minnesota, New Jersey, New York
2024-11-04
Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
NCT06544265B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
DrugSynKIR-310
Verismo Therapeutics
Phase 1
36
Colorado, Georgia, Kansas, New Jersey, Pennsylvania
2024-11-01
Active, closed
Boston Scientific Corporation
Not applicable
230
California, Florida, Georgia, Illinois, Kansas, New York, Ohio, Pennsylvania
2024-10-30
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
135
Arizona, California, District of Columbia, Florida, Illinois, Iowa, Kansas, Kentucky
2024-10-29
Recruiting
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
NCT06310031Cardiovascular Diseases, Heart Diseases, Heart Failure
BrioHealth Solutions, Inc.
Not applicable
780
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2024-10-28
Recruiting
Stemline Therapeutics, Inc.
Phase 1
240
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2024-10-25
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Massachusetts
2024-10-24
Recruiting
J-Valve Transfemoral Pivotal Study
NCT06455787Aortic Valve Regurgitation, Aortic Valve Disease Mixed
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Not applicable
194
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-10-17
Active, closed
Novartis Pharmaceuticals
Phase 2
251
California, Florida, Georgia, Kansas, Massachusetts, Nebraska, New York, North Carolina
2024-10-17
Active, closed
AstraZeneca
Phase 3
25
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2024-10-15
Recruiting
Study of ATX-01 in Participants With DM1
NCT06300307Myotonic Dystrophy 1
ARTHEx Biotech S.L.
Phase 1/2
56
California, Florida, Iowa, Kansas, Virginia
2024-10-15
Active, closed
Regenn® Therapy System Safety Study
NCT06259409Surgical Wound
Progenerative Medical, Inc
Phase 1
30
Kansas
2024-10-09
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-10-07
Recruiting
BeOne Medicines
Phase 1
310
Arizona, California, Colorado, Connecticut, Illinois, Kansas, Mississippi, New Jersey
2024-10-03
Recruiting
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Phase 1
256
California, Florida, Kansas, Massachusetts, Michigan, Missouri, New York, North Carolina
2024-10-03
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
349
California, District of Columbia, Florida, Illinois, Kansas, Massachusetts, Michigan, Minnesota
2024-10-02
Recruiting
Sardocor Corp.
Phase 1
12
Kansas, Ohio
2024-10-02
Recruiting
Aptevo Therapeutics
Phase 1
39
Colorado, Florida, Kansas, Ohio, Texas
2024-10-01
Recruiting
GlaxoSmithKline
Phase 2
393
Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2024-09-27
Recruiting
Catalyst Pharmaceuticals, Inc.
Observational
250
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kansas
2024-09-25
Active, closed
Cerevance
Phase 3
330
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas
2024-09-20
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
DrugsDoxorubicin·Paclitaxel
NiKang Therapeutics, Inc.
Phase 1
238
Arkansas, California, Colorado, Florida, Georgia, Kansas, Massachusetts, New Jersey
2024-09-19
Active, closed
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814Duchenne Muscular Dystrophy
NS Pharma, Inc.
Phase 1/2
20
California, Colorado, Illinois, Kansas, Pennsylvania
2024-09-18
Active, closed
Dianthus Therapeutics
Phase 2
46
Arizona, California, Florida, Hawaii, Kansas, Ohio, Texas
2024-09-17
Recruiting
Spirovant Sciences, Inc.
Phase 1/2
15
Kansas, Massachusetts, New York, Pennsylvania
2024-09-16
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland
2024-09-11
Active, closed
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
NCT05839730Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
105
Florida, Illinois, Kansas, North Carolina, Oklahoma, Texas, Vermont
2024-09-11
Recruiting
Gossamer Bio USA, Inc.
Phase 3
330
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Missouri
2024-09-03
Active, closed
Novo Nordisk A/S
Phase 1
63
Kansas, Texas, Utah
2024-09-03
Active, closed
Celgene
Phase 2
95
Alabama, Alaska, Arizona, California, District of Columbia, Florida, Kansas, Minnesota
2024-08-30
Active, closed
Sanofi
Phase 2
229
Arizona, California, Colorado, Florida, Idaho, Kansas, Massachusetts, Michigan
2024-08-29
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Arizona, California, Florida, Idaho, Kansas, Michigan, Missouri, North Carolina
2024-08-28
Active, closed
Regeneron Pharmaceuticals
Phase 4
120
California, Colorado, Florida, Idaho, Illinois, Kansas, Kentucky, Maine
2024-08-26
Recruiting
Opna Bio LLC
Phase 1
130
Arizona, California, Georgia, Kansas, Massachusetts, Michigan, New York, North Carolina
2024-08-22
Recruiting
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas
2024-08-21
Recruiting
BrainQ Technologies Ltd.
Not applicable
122
California, District of Columbia, Florida, Georgia, Illinois, Kansas, New Jersey, New York
2024-08-20
Recruiting
SuperSaturated Oxygen Comprehensive Observational Registry
NCT06438315STEMI - ST Elevation Myocardial Infarction, AMI
TherOx
Observational
1,000
California, Florida, Illinois, Kansas, Michigan, Minnesota, New Jersey, New York
2024-08-13
Recruiting
EFS of the DUO System for Tricuspid Regurgitation
NCT05913908Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
CroiValve Limited
Not applicable
15
Arizona, California, Georgia, Illinois, Kansas, Maine, Massachusetts, Minnesota
2024-08-13
Active, closed
Genmab
Phase 3
379
California, Colorado, Georgia, Illinois, Indiana, Kansas, Kentucky, Maryland
2024-08-13
Active, closed
Incyte Corporation
Phase 1
37
Alabama, California, Florida, Illinois, Kansas, Michigan, New York, Oregon
2024-08-08
Recruiting
Tempus AI
Observational
500
California, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2024-08-01
Active, closed
GlaxoSmithKline
Phase 3
10,212
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2024-08-01
Active, closed
UniQure Biopharma B.V.
Phase 1/2
20
Arizona, California, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2024-08-01
Recruiting
NovoCure GmbH
Phase 3
734
Alabama, Arizona, California, Florida, Illinois, Indiana, Kansas, Missouri
2024-07-31
Active, closed
Pfizer
Phase 2
605
Arkansas, California, District of Columbia, Florida, Idaho, Iowa, Kansas, Kentucky
2024-07-25
Active, closed
Avidity Biosciences, Inc.
Phase 2
84
California, Colorado, Florida, Georgia, Kansas, New York, North Carolina, Ohio
2024-07-25
Recruiting
GlaxoSmithKline
Phase 3
150
Florida, Kansas, Missouri, New Jersey, New York, Pennsylvania, Texas
2024-07-19
Recruiting
Jazz Pharmaceuticals
Phase 3
286
California, Colorado, Florida, Georgia, Kansas, Kentucky, Louisiana, Massachusetts
2024-07-19
Recruiting
Bristol-Myers Squibb
Phase 1/2
224
Alabama, California, Connecticut, Georgia, Illinois, Kansas, Maryland, Massachusetts
2024-07-17
Active, closed
Vor Biopharma
Phase 3
191
Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts
2024-07-17
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Florida, Illinois, Kansas, Michigan, Missouri, New York, Oregon, Virginia
2024-07-16
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Alabama, California, Colorado, Connecticut, Florida, Illinois, Kansas, Louisiana
2024-07-12
Active, closed
Pacira Pharmaceuticals, Inc
Not applicable
132
California, Florida, Georgia, Kansas, Missouri, New Jersey, New York, Pennsylvania
2024-07-11
Active, closed
Mesoblast, Ltd.
Phase 3
300
Arizona, California, Colorado, Florida, Georgia, Hawaii, Kansas, Kentucky
2024-07-03
Recruiting
GlaxoSmithKline
Phase 1
675
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2024-07-02
Recruiting
Cabaletta Bio
Phase 2/3
37
Connecticut, Florida, Illinois, Kansas, Michigan, Minnesota, New York, North Carolina
2024-07-02
Recruiting
Global Paradise System US Post Approval Study
NCT06297291Hypertension, Cardiovascular Diseases, Vascular Diseases
ReCor Medical, Inc.
Observational
1,000
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas, Louisiana
2024-06-28
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Arizona, Colorado, Connecticut, District of Columbia, Florida, Kansas, North Carolina, Ohio
2024-06-25
Recruiting
Takeda
Phase 4
60
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky
2024-06-12
Recruiting
UniQure Biopharma B.V.
Phase 1/2
12
Alabama, Arizona, California, Florida, Kansas, Maryland, Massachusetts, Michigan
2024-06-12
Active, closed
AskBio Inc
Phase 2
127
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-06-11
Active, closed
Natera, Inc.
Not applicable
250
California, Colorado, Florida, Kansas, Massachusetts, Michigan, New York, North Carolina
2024-06-10
Recruiting
Exact Sciences Corporation
Observational
1,800
Alaska, California, Colorado, Florida, Illinois, Indiana, Kansas, Kentucky
2024-06-07
Recruiting
Immunocore Ltd
Phase 3
680
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2024-06-05
Active, closed
Nexcella Inc.
Phase 1/2
45
California, Georgia, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New York
2024-06-05
Active, closed
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
NCT06106672Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
COUR Pharmaceutical Development Company, Inc.
Phase 1/2
54
Arizona, California, Connecticut, Florida, Illinois, Kansas, Michigan, Missouri
2024-05-30
Recruiting
Lomond Therapeutics Holdings, Inc.
Phase 1
150
California, Georgia, Illinois, Kansas, Maryland, New York, North Carolina, Ohio
2024-05-29
Recruiting
Post-Market Clinical Study of Functional Motion Outcomes in Subjects Treated With the Minuteman Device
NCT06355791Degenerative Conditions of the Lumbar Spine, Lumbar Spinal Stenosis, Spondylolisthesis
Spinal Simplicity LLC
Not applicable
150
Georgia, Indiana, Kansas, Minnesota, Oregon, West Virginia
2024-05-29
Recruiting
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC
DrugsRMC-9805·MFOLFIRINOX·MFOLFOX6·Folfox
Revolution Medicines, Inc.
Phase 1/2
1,130
Arizona, California, Colorado, Connecticut, Florida, Kansas, Maryland, Massachusetts
2024-05-24
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
DrugsBBO-10203·Pembrolizumab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
350
Alabama, California, Colorado, Connecticut, Illinois, Kansas, Maryland, Michigan
2024-05-22
Recruiting
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
NCT06116110Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma
Miltenyi Biomedicine GmbH
Observational
150
Arizona, California, Connecticut, Illinois, Kansas, Maryland, Massachusetts, North Carolina
2024-05-15
Recruiting
Eli Lilly and Company
Phase 3
510
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-04-29
Active, closed
Erasca, Inc.
Phase 3
78
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2024-04-29
Recruiting
Axsome Therapeutics, Inc.
Phase 3
450
California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri
2024-04-26
Active, closed
Sana Biotechnology
Phase 1
6
Kansas, Washington
2024-04-18
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Arkansas, California, Colorado, Florida, Illinois, Indiana, Kansas, Louisiana
2024-04-18
Recruiting
Takeda
Phase 4
50
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas
2024-04-18
Active, closed
argenx
Phase 3
119
Arizona, California, Florida, Georgia, Kansas, New Jersey, North Carolina, Ohio
2024-04-16
Recruiting
AbbVie
Phase 2/3
840
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Missouri
2024-04-10
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Arkansas, California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan
2024-04-09
Recruiting
A Study of IBI363 in Subjects with Advanced Solid Malignancies
NCT06281678Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
DrugLenvatinib
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
178
California, Florida, Kansas, Michigan, Texas, Washington
2024-04-08
Active, closed
Amgen
Phase 3
434
Arizona, California, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri
2024-04-08
Active, closed
VistaGen Therapeutics, Inc.
Phase 3
238
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Kansas
2024-03-28
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
120
Alabama, California, Colorado, Connecticut, Kansas, Massachusetts, Missouri, New Jersey
2024-03-28
Active, closed
AbbVie
Phase 2
156
California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana
2024-03-23
Recruiting
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
AstraZeneca
Phase 1
108
California, Florida, Illinois, Kansas, Massachusetts, Missouri, New York, Oregon
2024-03-22
Recruiting
Molecure S.A.
Phase 2
96
Alabama, Kansas, Maryland, Minnesota, Ohio, Pennsylvania, South Carolina
2024-03-21
Recruiting
ViiV Healthcare
Phase 1
372
Kansas, Texas, Utah
2024-03-21
Recruiting
Volta Medical
Observational
400
Illinois, Kansas, New York, Ohio
2024-03-19
Active, closed
Eli Lilly and Company
Phase 3
320
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Montana
2024-03-15
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Arkansas, California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas
2024-03-12
Recruiting
AstraZeneca
Phase 1/2
60
California, Florida, Georgia, Kansas, Massachusetts, Missouri, New Jersey, New York
2024-03-12
Recruiting
AtriCure, Inc.
Observational
10,000
Alabama, Arkansas, California, Colorado, District of Columbia, Florida, Indiana, Kansas
2024-03-11
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New Jersey
2024-03-07
Recruiting
Takeda
Phase 2
268
California, Florida, Georgia, Iowa, Kansas, Kentucky, Maryland, Missouri
2024-03-05
Active, closed
Youssef Yammine
Phase 3
100
Kansas
2024-03-01
Active, closed
A Study in Patients With Mixed Dyslipidemia
NCT06497127Mixed Dyslipidemia
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
145
Alabama, Florida, Georgia, Illinois, Kansas, New York, Oklahoma, Texas
2024-02-28
Active, closed
Cardiff Oncology
Phase 2
110
Arizona, Arkansas, California, Florida, Hawaii, Indiana, Kansas, Michigan
2024-02-27
Active, closed
Dianthus Therapeutics
Phase 2
65
Arizona, California, Connecticut, Florida, Illinois, Kansas, Kentucky, Massachusetts
2024-02-23
Recruiting
Kura Oncology, Inc.
Phase 1
171
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Iowa, Kansas
2024-02-22
Active, closed
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT05996003Duchenne Muscular Dystrophy, Exon 44, DMD
DrugBrogidirsen
NS Pharma, Inc.
Phase 2
20
Colorado, Georgia, Illinois, Kansas, Massachusetts, New York, Ohio, Pennsylvania
2024-02-22
Recruiting
Sonavex, Inc.
Not applicable
304
Alabama, Arizona, Florida, Illinois, Kansas, Massachusetts, Michigan, New Jersey
2024-02-21
Active, closed
Parkinson's Disease Progression Study
NCT06219629Parkinson Disease
Koneksa Health
Observational
82
Colorado, Florida, Georgia, Kansas, Massachusetts, Michigan, Nevada
2024-02-20
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 1/2
47
California, Florida, Kansas, Massachusetts, Missouri, North Carolina, Pennsylvania, Virginia
2024-02-20
Recruiting
Cabaletta Bio
Phase 1/2
28
California, Connecticut, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2024-02-16
Recruiting
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor
Frontier Medicines Corporation
Phase 1/2
403
California, Florida, Indiana, Kansas, Massachusetts, Michigan, Pennsylvania, Texas
2024-02-12
Recruiting
Pfizer
Phase 3
492
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2024-02-08
Active, closed
ZILRETTA in Subjects With Shoulder Osteoarthritis
NCT06269705Glenohumeral Osteoarthritis
Pacira Pharmaceuticals, Inc
Phase 3
150
Alabama, Arizona, California, District of Columbia, Florida, Idaho, Kansas, Louisiana
2024-02-05
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Alabama, Alaska, Arizona, California, Georgia, Illinois, Indiana, Kansas
2024-02-05
Active, closed
Astellas Gene Therapies
Not applicable
119
Georgia, Kansas, Michigan, Minnesota, New Jersey, Ohio, Pennsylvania, Utah
2024-02-01
Recruiting
Cumberland Pharmaceuticals
Phase 2
128
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Michigan
2024-01-31
Active, closed
BicycleTx Limited
Phase 2
375
Colorado, Florida, Kansas, Kentucky, Nebraska, New York, South Carolina, Tennessee
2024-01-24
Active, closed
DualityBio Inc.
Phase 3
541
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas
2024-01-18
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsErbitux·Cetuximab
AVEO Pharmaceuticals, Inc.
Phase 3
410
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-01-11
Active, closed
AbbVie
Phase 2/3
89
California, Illinois, Kansas, Kentucky, Michigan, Minnesota, Missouri, Texas
2024-01-11
Recruiting
GluBio Therapeutics Inc.
Phase 1
48
California, Kansas, New York, Texas
2024-01-11
Recruiting
Axsome Therapeutics, Inc.
Phase 4
350
California, Florida, Georgia, Illinois, Kansas, Louisiana, Massachusetts, Missouri
2023-12-27
Active, closed
TVAX Biomedical
Phase 2/3
120
Arizona, California, Florida, Georgia, Kansas, New Jersey, Oregon
2023-12-27
Recruiting
Clarity Pharmaceuticals Ltd
Phase 3
383
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Kansas
2023-12-21
Recruiting
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT06154252Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy
Cabaletta Bio
Phase 2/3
74
California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2023-12-20
Active, closed
AstraZeneca
Phase 1/2
94
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, New Jersey
2023-12-14
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic
DrugsRetifanlimab·Cyclophosphamide
BriaCell Therapeutics Corporation
Phase 3
404
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2023-12-05
Recruiting
Incyte Corporation
Phase 1
290
California, Florida, Kansas, Maryland, Massachusetts, Missouri, New York, North Carolina
2023-12-04
Recruiting
GIE Medical
Phase 3
198
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2023-12-01
Active, closed
argenx
Observational
413
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2023-11-29
Recruiting
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Endotronix, Inc.
Not applicable
1,750
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Maryland
2023-11-29
Recruiting
Freenome Holdings Inc.
Observational
20,000
California, Connecticut, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2023-11-28
By invitation
CRISPR Therapeutics AG
Observational
70
California, Connecticut, Georgia, Illinois, Kansas, Minnesota, Missouri, New York
2023-11-22
Recruiting
Edwards Lifesciences
Not applicable
200
California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2023-11-22
Active, closed
Regeneron Pharmaceuticals
Phase 3
733
Florida, Indiana, Kansas, Kentucky, Michigan, Texas, Utah, Wisconsin
2023-11-14
Active, closed
AstraZeneca
Phase 3
314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2023-11-08
Recruiting
GIE Medical
Phase 3
171
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky
2023-11-01
Recruiting
United Therapeutics
Phase 3
698
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-10-30
Active, closed
Novartis Pharmaceuticals
Phase 3
612
California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland, Massachusetts
2023-10-27
By invitation
Eledon Pharmaceuticals
Phase 2
132
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2023-10-25
Active, closed
AskBio Inc
Phase 2
150
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Kansas
2023-10-20
Active, closed
Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR
NCT05295628Aortic Valve Stenosis, Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Valve Replacement
Emblok, Inc.
Not applicable
532
Arizona, California, Connecticut, District of Columbia, Illinois, Iowa, Kansas, Louisiana
2023-10-17
Active, closed
Eli Lilly and Company
Phase 3
160
Georgia, Idaho, Kansas, Louisiana, Maryland, Minnesota, Missouri, Ohio
2023-10-16
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Alabama, Arizona, California, Florida, Indiana, Kansas, Kentucky, Maryland
2023-10-13
Active, closed
Bristol-Myers Squibb
Phase 3
106
California, Connecticut, Florida, Kansas, Kentucky, Michigan, Missouri, New Jersey
2023-10-05
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
92
California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Michigan
2023-09-22
Active, closed
Attralus, Inc.
Phase 2
120
Kansas, Ohio, Oregon, Pennsylvania
2023-09-21
Active, closed
Real World Registry for Use of the Ion Endoluminal System
NCT06004440Lung Cancer, Multiple Pulmonary Nodules, Lung Neoplasms, Respiratory Tract Neoplasms
Intuitive Surgical
Observational
1,301
Florida, Illinois, Kansas, Louisiana, Michigan, Minnesota, New York, North Carolina
2023-09-21
Recruiting
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
NCT06034327Myopia, Juvenile Myopia, Myopia Progression
SightGlass Vision, Inc.
Not applicable
150
California, Florida, Georgia, Illinois, Kansas, Massachusetts, Missouri, Ohio
2023-09-18
Active, closed
Bristol-Myers Squibb
Phase 3
774
California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2023-09-11
Active, closed
Boehringer Ingelheim
Phase 2
268
California, Florida, Kansas, New York, Ohio, South Carolina, Texas
2023-09-08
Recruiting
IC-8 Apthera IOL New Enrollment Post Approval Study
NCT06060041Cataract, Presbyopia, Posterior Capsule Opacification
Bausch & Lomb Incorporated
Observational
435
Alabama, California, Florida, Illinois, Indiana, Kansas, Michigan, Nebraska
2023-09-08
Recruiting
Ipsen
Phase 3
276
Arizona, Arkansas, California, Colorado, Florida, Kansas, Louisiana, Michigan
2023-08-31
Active, closed
Bavarian Nordic
Phase 3
715
Alabama, Arizona, Florida, Illinois, Kansas, Kentucky, Missouri, Nevada
2023-08-30
Active, closed
ModernaTX, Inc.
Phase 1/2
1,407
California, Colorado, Florida, Georgia, Idaho, Illinois, Iowa, Kansas
2023-08-25
Recruiting
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
NCT05677100Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF
Procyrion
Not applicable
320
Arizona, California, Florida, Georgia, Illinois, Kansas, Michigan, Mississippi
2023-08-23
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Florida, Georgia, Kansas, Michigan, New Jersey, New York, Oregon, Rhode Island
2023-08-18
Active, closed
AstraZeneca
Phase 3
100
Arizona, Arkansas, California, Colorado, Florida, Indiana, Kansas, Maryland
2023-08-11
Active, closed
The BD Liverty™ TIPS Stent Graft Study
NCT05711316Portal Hypertension, TIPS
C. R. Bard
Not applicable
177
California, District of Columbia, Indiana, Kansas, Massachusetts, Missouri, New Jersey, New York
2023-08-08
Recruiting
GlaxoSmithKline
Phase 3
892
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-08-01
Recruiting
Incyte Corporation
Observational
1,500
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2023-08-01
Active, closed
Abbott Ventricular Tachycardia PAS
NCT05839873Ventricular Tachycardia
Abbott Medical Devices
Observational
62
Florida, Indiana, Kansas, Massachusetts, Minnesota, North Carolina, Oklahoma, South Carolina
2023-07-24
Recruiting
Lin BioScience, Inc
Phase 1/2
90
Florida, Illinois, Kansas, Maryland, North Carolina
2023-07-20
Active, closed
Amulet™ ADVANCE LAA
NCT05997446Atrial Fibrillation, Stroke, Bleeding
Abbott Medical Devices
Observational
610
Arizona, Arkansas, Florida, Illinois, Kansas, Michigan, Nebraska, New York
2023-07-12
Recruiting
Encore PFO Closure Device - The PerFOrm Trial
NCT05537753Patent Foramen Ovale, Cryptogenic Stroke
Encore Medical Inc.
Not applicable
500
Arkansas, California, Florida, Iowa, Kansas, Mississippi, Nebraska, South Carolina
2023-07-12
Active, closed
OncoC4, Inc.
Phase 3
630
Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Kansas
2023-06-28
Active, closed
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Theravance Biopharma
Phase 3
102
Arizona, California, District of Columbia, Florida, Georgia, Hawaii, Illinois, Kansas
2023-06-27
Active, closed
Myopia Control Spectacle Lens Cessation Study
NCT05893979Myopia, Myopia Progression, Juvenile Myopia
SightGlass Vision, Inc.
Not applicable
90
California, Florida, Kansas, Missouri, New York, Tennessee, Texas, Utah
2023-06-23
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2023-06-22
Active, closed
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
NCT05893498Percutaneous Coronary Intervention
CathWorks Ltd.
Not applicable
1,924
California, Florida, Georgia, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2023-06-21
By invitation
AbbVie
Phase 3
650
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas
2023-06-05
Active, closed
Eli Lilly and Company
Phase 3
3,127
Arizona, California, Colorado, Florida, Georgia, Hawaii, Idaho, Kansas
2023-06-05
Active, closed
Synergy Spine Solutions
Not applicable
200
Arizona, California, Colorado, Florida, Indiana, Kansas, Louisiana, Michigan
2023-06-01
Active, closed
ML Bio Solutions, Inc.
Phase 3
112
Arkansas, California, Colorado, Florida, Iowa, Kansas, Maryland, Minnesota
2023-05-31
Active, closed
Beam Therapeutics Inc.
Phase 1/2
5
California, Colorado, Illinois, Kansas, Massachusetts, Ohio, Oregon, Pennsylvania
2023-05-25
Active, closed
iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction
NCT05870488Sacroiliac Joint Dysfunction, Sacroiliac; Fusion, Sacroiliac Disorder, Sacroiliac Joint Pain
SI-BONE, Inc.
Phase 4
110
California, Indiana, Kansas, Kentucky, Maryland, Missouri, Nevada, Oklahoma
2023-05-23
Active, closed
Assessment of Combined CCM and ICD Device in HFrEF
NCT05855135Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy
Impulse Dynamics
Not applicable
300
Arizona, California, Connecticut, Florida, Iowa, Kansas, Kentucky, Massachusetts
2023-05-17
Active, closed
Francis Medical Inc.
Not applicable
400
Arizona, California, Florida, Illinois, Kansas, Maryland, Michigan, Minnesota
2023-05-16
Active, closed
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
NCT05230459Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2, LGMD2I, Muscular Dystrophy
AskBio Inc
Phase 1/2
9
California, Iowa, Kansas, Maryland, Virginia, Washington
2023-05-15
Active, closed
Gilead Sciences
Phase 3
654
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas, Louisiana
2023-05-08
Active, closed
Shockwave Medical, Inc.
Observational
399
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas, Louisiana
2023-05-03
Active, closed
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
DrugDupilumab
Regeneron Pharmaceuticals
Phase 2
22
Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas, Massachusetts
2023-05-03
Recruiting
Intra-Cellular Therapies, Inc.
Phase 3
470
Alabama, California, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri
2023-05-02
Active, closed
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
NCT05878184Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
DrugsSC291·Fludarabine·Cyclophosphamide
Sana Biotechnology
Phase 1
16
California, Georgia, Kansas, Michigan, Nebraska, Texas
2023-05-02
Recruiting
AbbVie
Phase 3
450
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas
2023-05-01
Active, closed
Nalu Medical, Inc.
Not applicable
185
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Michigan, New Jersey
2023-04-27
Active, closed
AstraZeneca
Phase 2
294
Alabama, California, Kansas, New York
2023-04-24
Active, closed
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT05626855Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA
DrugApitegromab
Scholar Rock, Inc.
Phase 3
238
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Maryland
2023-04-17
Recruiting
GEn1E Lifesciences
Phase 2
52
District of Columbia, Kansas, Maryland, Mississippi, Missouri, New Jersey, New York, Ohio
2023-04-04
Active, closed
Edwards Lifesciences
Not applicable
100
California, Illinois, Kansas, Minnesota, New York, Ohio, Oklahoma, Oregon
2023-04-01
Active, closed
Bial R&D Investments, S.A.
Phase 2
237
Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas
2023-03-31
Recruiting
Iovance Biotherapeutics, Inc.
Phase 3
670
Alabama, California, Colorado, Florida, Illinois, Kansas, Kentucky, Maryland
2023-03-30
Recruiting
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
NCT05568680Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant
Verismo Therapeutics
Phase 1
42
Florida, Kansas, Pennsylvania, Texas, Wisconsin
2023-03-30
Active, closed
Pfizer
Phase 1/2
936
Arizona, California, Florida, Illinois, Kansas, Minnesota, Missouri, New York
2023-03-23
Active, closed
Merck Sharp & Dohme LLC
Phase 2
129
California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky, Michigan
2023-03-16
Recruiting
Vivistim Registry for Paired VNS Therapy (GRASP)
NCT05301140Upper Extremity Problem
MicroTransponder Inc.
Observational
1,000
Florida, Illinois, Kansas, Kentucky, New Jersey, New York, Pennsylvania, Texas
2023-03-15
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05643742B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
DrugZugo-cel
CRISPR Therapeutics AG
Phase 1/2
120
Kansas, Missouri, Texas, Utah
2023-03-10
Recruiting
A Study of BLB-201 RSV Vaccine in Infants and Children
NCT05655182Respiratory Syncytial Virus Infections
Blue Lake Biotechnology Inc.
Phase 1/2
137
California, Colorado, Georgia, Idaho, Kansas, Louisiana, Michigan, Nebraska
2023-03-09
Active, closed
AlgoTherapeutix
Phase 2
276
Florida, Kansas, Maryland, New York, Texas
2023-02-28
Recruiting
Housey Healthcare ULC
Phase 2
300
California, Florida, Georgia, Kansas, Louisiana, Michigan, Nebraska, Nevada
2023-02-03
Rows per page Showing 1–500 of 747
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/kansas

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 747 of those studies with a site in Kansas.

How many clinical trials are recruiting in Kansas?

374 of the 747 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 11 have not yet opened recruitment, 346 are active but closed to new participants, and 16 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kansas), 747 studies
PhaseStudiesRecruitingShare
Phase 32369531.6%
Phase 21608221.4%
Not applicable1014313.5%
Phase 1855711.4%
Observational64388.6%
Phase 1/262368.3%
Phase 2/322152.9%
Phase 41782.3%

Most active sponsors

Lead sponsors with the most studies (Kansas)
Lead sponsorStudiesRecruiting
AstraZeneca3916
Janssen Research & Development, LLC2210
Novartis Pharmaceuticals2014
Eli Lilly and Company177
Pfizer168
GlaxoSmithKline1511
Sanofi1410
AbbVie127
Merck Sharp & Dohme LLC124
Abbott Medical Devices113
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.